Endocannabinoids and opioids play a vital role in mediating pain-induced analgesia. The specific effects of these compounds within the orofacial region are largely unknown. In this study, we tried to determine whether an increase in cannabinoid and opioid concentration in the CSF affects impulse transmission between the motor centres localized in the vicinity of the third and fourth cerebral ventricles.
Introduction
Orofacial pain disorders are frequent in the general population; up to 26% adults suffer from such problems at some point of their life. Pharmacological treatment of orofacial pain is difficult and controversial (Tzabazis et al., 2014; Weiss et al., 2017) .
It has been demonstrated that the endogenous opioid system could be involved in cannabinoid antinociception, and recent data have also provided evidence for a role of the endogenous cannabinoid system in opioid antinociception (Cichewicz, 2004; Bushlin et al., 2010; Wilson-Poe et al., 2013) .
The opioid receptor system includes three subtypes of receptors, μ, δ and κ, and the endogenous opioid peptides, β-endorphin, enkephalins, dynorphins and endomorphins, that can activate these receptors (Kieffer, 1995) . The cannabinoid system comprises the two major cannabinoid receptors, CB 1 and CB 2 receptors, their endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), which regulate their biosynthesis and degradation (Di Marzo et al., 2004) . Simultaneous activation of opioid and cannabinoid receptors can produce synergistic analgesic effects (Smith et al., 1998; Seely et al., 2012) . Opioids and cannabinoids produce antinociception through separate (although possibly interrelated) mechanisms (Cichewicz, 2004; Tham et al., 2005; Roberts et al., 2006) . They also exhibit overlapping neuroanatomical distribution and comparable functional neurobiological properties (Nawarro et al., 2001) . Both receptor types are found in several brain regions known to participate in antinociception, including the periaqueductal central gray (PAG), raphe nuclei and central medial thalamic nuclei (Manzanares et al., 1999; Cichewicz, 2004) , suggesting that they may either act alone or in tandem, to produce antinociception. Furthermore, μ and CB 1 receptors have been shown to colocalize to the same neurons within the superficial dorsal horn of the spinal cord (Hohmann et al., 1999; Salio et al., 2001) , the first site of synaptic contact for peripheral nociceptive afferents, raising the possibility of direct interactions between these receptor types on the same cell.
Opioid and cannabinoid receptors also share similar signal transduction pathways. Both belong to the GPCR family that couple to Gα i/o to inhibit the activity of adenylyl cyclase, blocking cAMP production; MAP kinases are activated through other second messenger systems and inhibit neurotransmitter release via inhibition of calcium channels and activation of potassium channels (Salio et al., 2001; Cichewicz, 2004; Demuth and Molleman, 2006) . Both receptor types are generally found on presynaptic terminals, a location that is consistent with the inhibition of neurotransmitter release (Hohmann et al., 1999; Salio et al., 2001; Ohno-Shosaku and Kano, 2014) . These data raise the intriguing possibility that opioid and cannabinoid receptors function together within the same cell or neuronal circuit to produce antinociception and that modulation of one receptor system may lead to alterations in the activity of the other.
Interactions between endocannabinoids (ECs) and the opioid system during antinociception have been evaluated using cannabinoid receptor antagonists or inhibitors of enzymes that degrade ECs. Studies showing that treatment with cannabinoid receptor agonists can lead to opioid peptide release and that ECs are involved in the actions of opioid agonists confirm the synergistic interactions between these two receptor systems (Cichewicz, 2004; .
It is generally accepted that in rats, tooth pulp stimulation represents a valuable pain model and has been proposed as a model for trigeminal pain (Chapman et al., 1986) . The trigemino-hypoglossal reflex has been used in our laboratory for over a decade to study the conductivity of nociception within the brainstem. In this pain model, the amplitude of the evoked tongue jerks (ETJ) induced by tooth pulp stimulation is recorded. The magnitude of ETJ during perfusion of the cerebral ventricles with the neurotransmitters under investigation can be a measure of the effect of these compounds on the neural structures (Zubrzycka et al., 1997; Zubrzycki et al., 2015) .
Here, the trigemino-hypoglosal reflex model was used to study the efficacy of ECs, inhibitors of their degrading enzymes and opioids, applied separately or in combination, as a treatment of orofacial pain.
Methods

Animals and anaesthesia
Male Long Evans rats weighing (330-350 g) were used for all experiments. The animals were housed at a constant temperature (22-24°C) and maintained in sawdust-lined plastic cages under a 12 h light/dark cycle with free access to laboratory chow and tap water ad libitum. The rats were anaesthetized with a single i.p. injection of chloralose solution at a dose of 150 mg·kg À1 body weight. In all the experimental animals the anaesthesia persisted for the whole period of the experiment. For each experiment, six animals were used. The experimental protocol in the present study was approved by the Local Ethical Committee for Animal Research and it complies with the European Community guidelines for the use of experimental animals (Zimmermann, 1983) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Care was taken to reduce both the number of animals used and their suffering during the experiments.
Perfusion of cerebral ventricles in rats
The rat's head was immobilized by introduction of ear bars into the external auditory meati and fixing the maxilla with jaw clamps in a stereotaxic instrument specially adapted for perfusion of the cerebral ventricles (Zubrzycka et al., 1997) . The skin of the animal's head, anaesthetized with 2% polocaine solution, was incised at the midline and the skull bones were exposed. On the basis of co-ordinates given by Paxinos and Watson (2005) stereotaxic atlas, the sites for drilling holes in the skull bones were determined in relation to the lateral ventricles -9 mm anterior to the frontal interaural zero plane and 3 mm lateral to the sagittal zero plane. The system of cerebral ventricles was perfused by inserting stainless steel cannulae into both lateral ventricles and to the cerebellomedullary cistern. The container with perfusion fluid was positioned 20 cm above the animal's head. The outflow cannula, inserted into the cerebellomedullary cistern, was connected to a polyethylene tube approximately 100 cm long, which provided the outflow for the perfusion fluid. The flow rate at the end of the tubing during perfusion was 0.5-0.7 mL·10 min À1 . After a control perfusion with artificial CSF (aCSF), the cerebral ventricles were perfused with peptide solutions. There were 5 min intervals between the administration of different solutions.
Tooth pulp stimulation
After the animal's head had been placed in a stereotaxic instrument, the tips of both lower incisors were cut off with a dental separator, and stainless steel wire electrodes were inserted into the pulp and fixed with dental cement (Duracil, Spofa). The pulp bipolar stimulation was delivered six times min À1 , with a train of four electrical impulses, of 200 Hz frequency, 3 ms single impulse duration with 2 ms intervals and 4-6 V amplitude, using a programmed stimulator. Trains of four impulses were delivered to the pulp at 10 s intervals. A Grass stimulator, model S4K, connected with a gating circuit, was used. At the beginning of each experiment, the intensity of stimulus inducing maximal tongue jerks was determined. The amplitude of electrical impulses was adjusted so that each impulse caused a distinct sharp backward movement of the stretched tongue to obtain a recorded amplitude of about 20 mm, which was a half of the maximal response. Throughout the whole experiment, the tongue was stretched with the same force, about 5.8 G, by the lever of a strain gauge isotonic transducer, and the adjusted amplitude was determined individually for each animal.
Recording tongue jerks
The method used here was developed and is still used in our laboratory (Zubrzycka et al., 1997; .
The tip of the animal's tongue was attached with a silk thread to an isotonic rotating tensometric transducer. The tongue was stretched with the same force throughout the experiment, the amplification of the recorder also remained unchanged. For each animal, during the first 10 min of perfusion the amplitude of ETJ induced by tooth pulp stimulation was recorded. The ETJ amplitudes recorded on the tape during each 10 min period were measured in mms, and the mean ETJ amplitude was obtained. The mean amplitude of ETJ was regarded as an indicator of the magnitude of the trigemino-hypoglossal reflex.
Data analysis
Statistical analyses were performed using Prism 5.0 (GraphPad Software Inc.). The data are expressed as means ± SEM. Differences between groups were assessed by one-way ANOVA followed by a post hoc multiple comparison Student Newman-Keuls test. P < 0.05 was considered to be statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Drugs
The composition of aCSF was as follows: 120 mM NaCl, 4.8 mM KCl, 2.8 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.3 mM MgSO 4 , 26 mM NaHCO 3 , 10 mM glucose, 1.0 g . L -1 BSA and 0.1 g . L -1 ascorbic acid (pH = 7.4-7.5). The solution was placed in a water bath at 37°C and constantly gassed with carbogen (a mixture of 95% O 2 , and 5% CO 2 ). AEA, 2-AG, endomorphin-2 (EM-2), β-funaltrexamine
piperazine-1-carboxylate (JZL195) were purchased from Tocris Bioscience (Bristol, UK).
Solutions for i.c.v. perfusions were prepared in aCSF at a concentration of 50 and 100 nM.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
To determine which ECs modulate the opioidergic synaptic transmission in orofacial pain, the effects of i.c.v. administration of AEA or 2-AG on the trigeminio-hypoglossal reflex were examined in the presence of opioid or cannabinoid agonists and inhibitors of cannabinoid degrading enzymes.
Influence of AEA alone or in combinations on the trigemino-hypoglossal reflex in rats Antinociceptive activity of AEA alone. Perfusion of cerebral ventricles with AEA caused a significant reduction of the amplitude of ETJ, as compared to control perfusion with aCSF. The analgesic activity of AEA, expressed as the ETJ amplitude, was concentration-dependent as perfusion with 50 and 100 nM solutions reduced the ETJ amplitude compared to control, regarded as a 100% (Figure 1 ).
Antinociceptive activity of AEA co-administered with CB 1 receptor antagonist AM251 or μ receptor-selective antagonist β-FNA. AM251 or β-FNA at 100 nM preceded the perfusion of AEA. AM251 decreased the antinociceptive effect produced by AEA as it increased the amplitude of the ETJ (Figure 2A) . A similar effect was observed when cerebral ventricles were perfused with β-FNA ( Figure 2B ). These results confirm that the antinociceptive activity of AEA was mediated by CB 1 and μ receptors.
Antinociceptive activity of AEA co-administered with FAAH inhibitor, URB597 and CB 1 receptor antagonist AM251. The antinociceptive activity of AEA (100 nM) was significantly increased when this EC was perfused in combination with the FAAH inhibitor, URB597 (100 nM). The ETJ amplitude was decreased by AEA and was enhanced when URB597 was administered together with AM251, compared to control, which was regarded as a 100% ( Figure 3A) .
Inhibition of FAAH potentiated the antinociceptive activity of AEA, and this effect was reversed by concomitant administration of a CB 1 receptor antagonist.
Antinociceptive activity of AEA co-administered with MAGL inhibitor, JZL184. Perfusion of cerebral ventricles with JZL184, an inhibitor of 2-AG-hydrolyzing enzyme, MAGL, had no effect on the antinociceptive activity of AEA ( Figure 3B ).
Antinociceptive activity of AEA co-administered with FAAH/MAGL dual inhibitor, JZL195. Perfusion of cerebral ventricles with AEA in combination with JZL195 caused a significant reduction in the amplitude of ETJ compared to control perfusion with aCSF ( Figure 3C) . A dual FAAH/MAGL inhibitor showed a greater potential to alleviate orofacial pain compared to selective inhibitors.
Influence of 2-AG alone or in combinations on the trigemino-hypoglossal reflex in rats Antinociceptive activity of 2-AG alone. Perfusion of cerebral ventricles with 2-AG had no effect on the amplitude of ETJ as compared with control perfusion with aCSF. The activity of 2-AG, expressed as the amplitude of the ETJ did not depend on concentration, and the values for the perfusion with 50 and 100 nM solutions were not different from the control, regarded as 100% (Figure 4 ).
Antinociceptive activity of 2-AG co-administered with MAGL hydrolysing enzyme inhibitor, JZL184 and CB 1 receptor antagonist AM251. The activity of 2-AG, expressed as the amplitude of ETJ, was slightly decreased when 2-AG was perfused in combination with JZL184, but this effect was reversed by addition of AM251 ( Figure 5 ).
Influence of EM-2 alone or in combinations on the trigemino-hypoglossal reflex in rats Antinociceptive activity of EM-2 alone. Perfusion of cerebral ventricles with EM-2 caused a significant, concentrationdependent reduction in the amplitude of ETJ compared to control perfusion with aCSF ( Figure 6 ).
Antinociceptive activity of EM-2 co-administered with selective μ receptor antagonist β-FNA or selective CB 1 receptor antagonist AM251. Perfusions of cerebral ventricles with the selective μ receptor antagonist, β-FNA or CB 1 antagonist AM251, which preceded perfusion with EM-2 (all at 100 nM concentrations), were performed. As expected, β-FNA decreased the antinociceptive effect produced by EM-2 ( Figure 7A) . A similar effect was observed when perfusion with EM-2 was preceded by AM251 ( Figure 7B ). These results show that EM-2 can activate both types of receptors, μ and CB 1 receptors, either directly or through the downstream metabolites common for both receptors.
Antinociceptive activity of EM-2 co-administered with FAAH inhibitor, URB597. The antinociceptive activity of EM-2, expressed as the amplitude of ETJ, was slightly enhanced when it was perfused in combination with URB597 ( Figure 8A ). Effects of perfusion of cerebral ventricles with aCSF and with 50 and 100 nM AEA in rats on ETJ induced by tooth pulp stimulation. The data represent mean ± SEM of six rats per group. Amplitude of ETJ after i.c.v. perfusion with aCSF was considered a 100% response. Statistical analyses were performed with one-way ANOVA followed by a post hoc multiple comparison Student Newman-Keuls test. *P < 0.05 as compared with control, F(2.15) = 4.779.
Antinociceptive activity of EM-2 co-administered with CB 1 receptor agonist AEA. The antinociceptive activity of EM-2 (100 nM), expressed as the amplitude of the ETJ, was slightly enhanced when EM-2 was perfused through the cerebral ventricles in combination with AEA (100 nM) ( Figure 8B ).
Discussion
Understanding the pathophysiology of pain disorders arising from structures innervated by the trigeminal nerve is still limited because of the paucity of animal models and reliable
Figure 4
Effects of perfusion of cerebral ventricles with aCSF and with 50 and 100 nM 2AG in rats on ETJ induced by tooth pulp stimulation. The data represent mean ± SEM of six rats per group. Amplitude of ETJ after i.c.v. perfusion with aCSF was considered a 100% response. Statistical significance was assessed using one-way ANOVA and a post hoc multiple comparison Student Newman-Keuls test. F (2,15) = 0.02754.
Figure 5
Effects of perfusion of cerebral ventricles with aCSF and with 2-AG and MAGL inhibitor, JZL184 and CB 1 receptor antagonist, AM251, all at 100 nM, in rats on ETJ induced by tooth pulp stimulation. The data represent mean ± SEM of six rats per group. Amplitude of ETJ after i.c.v. perfusion with aCSF was considered a 100% response. Statistical significance was assessed using one-way ANOVA and a post hoc multiple comparison Student Newman-Keuls test. F(4,25) = 1.609. methods of measuring evoked orofacial pain. It is believed that pathophysiology of orofacial pain involves the release of neurotransmitters via the activation of trigeminal afferents (Akerman et al., 2007 (Akerman et al., , 2013 Zubrzycki et al., 2015) .
Several lines of evidence have recently suggested that opioid and cannabinoid receptors can functionally interact in the CNS. These interactions may be direct, through receptor heteromerization, or indirect, through signalling cross-talk that includes agonist-mediated release and/or synthesis of endogenous ligands that can activate downstream receptors (Bushlin et al., 2012) .
Studies on the mechanisms underlying the analgesic effects of opioids and cannabinoids have largely focused on the GABA-ergic system within the PAG . Like opioids, cannabinoids are thought to produce analgesia by suppressing GABA-ergic inhibition of PAG output neurons, which project along a descending analgesic pathway (Fields et al., 2006; . ECs are described as 'synaptic circuit breakers' (Katona and Freund, Figure 6 Effects of perfusion of cerebral ventricles with aCSF and with 50 and 100 nM EM-2 in rats on ETJ induced by tooth pulp stimulation. The data represent mean ± SEM of six rats per group. Amplitude of ETJ after i.c.v. perfusion with aCSF was considered a 100% response. Statistical analyses were performed with one-way ANOVA followed by a post hoc multiple comparison Student Newman-Keuls test. *P < 0.05 as compared with control, F(2,15) = 12.13.
Figure 7
Effects of antagonists: (A) μ receptor-selective β-FNA and (B) CB 1 receptor antagonist, AM251 at 100 nM, on the amplitude of ETJ induced by tooth pulp stimulation during perfusion of cerebral ventricles with 100 nM EM-2. The data represent mean ± SEM of six rats per group. Amplitude of ETJ after i.c.v. perfusion with aCSF was considered a 100% response. Statistical analyses were performed with one-way ANOVA followed by a post hoc multiple comparison Student Newman-Keuls test. *P < 0.05 as compared with control. # P < 0.05 for EM-2 + β-FNA, F(3,20) = 9.96 (A); + P < 0.05 for EM-2 + AM251 versus EM-2, F(3,20) = 16.54 (B).
Figure 8
Effects of perfusion of cerebral ventricles with aCSF and with EM-2 and with: (A) FAAH inhibitor, URB597 (B) CB 1 agonist AEA, all at 100 nM, in rats on ETJ induced by tooth pulp stimulation. The data represent mean ± SEM of six rats per group. Amplitude of ETJ after i.c.v. perfusion with aCSF was considered a 100% response. Statistical analyses were performed with one-way ANOVA followed by a post hoc multiple comparison Student Newman-Keuls test. *P < 0.05 as compared with control F(3,20) = 8.12 (for A and B). 2012), acting as retrograde neurotransmitters in the PAG and rostral ventromedial medulla, inhibiting GABA-ergic and glutamatergic transmission by preventing the release of transmitters from nerve terminals, via activation of CB1 receptors (Vaughan et al., 1999 (Vaughan et al., , 2000 .
Here, we examined the role of the EC and opioid systems in the orofacial pain. As an opioid peptide, we used EM-2, which is an extremely potent and selective μ receptor agonist. Our experiments in rats demonstrated that EM-2 acts as a strong antinociceptive agent not only through presynaptic μ receptors but also through CB 1 receptors co-existing in numerous CNS structures. Similarly, a CB 1 receptor ligand AEA was shown to act through CB 1 and μ receptors.
CB 1 receptors are localized on fibres in the spinal trigeminal tract, found on large diameter myelinated fibres and in the nucleus trigeminalis caudalis (Tsou et al., 1998; Price et al., 2003) . Therefore, it is also possible that AEA exerts a direct effect upon trigeminal neurons (Akerman et al., 2004) to cause inhibition of CGRP release from central terminals of primary afferent fibres and to reduce the nociceptive behaviour. It was postulated that in addition to cannabinoid receptors, also, other receptor types may participate in mediation of analgesic effect of AEA (Maione et al., 2006) . Ahluwalia et al. (2003) showed that depending on AEA concentration, this EC can either inhibit (through CB 1 ) or stimulate [through transient receptor potential vanilloid 1 (TRPV1)] the release of CGRP within primary sensory neurons and branches of the trigeminal nerve. In the antinociceptive activity of AEA within the trigeminocervical complex, the 5-HT receptors are also engaged (Akerman et al., 2013) . Within the brainstem, EC and opioid systems can modulate the effects of each other in the way that both spinal and trigeminal nociceptive inputs are processed.
As the elements involved in the trigemino-hypoglossal reflex arc (Figure 9 ) are located in the vicinity of the cerebral ventricles, it can be assumed that β-FNA and AM251 injected into the cerebral ventricles permeated through the cerebroventricular lining and exerted their effects on the adjacent structures.
Blocking opioid and cannabinoid receptors with their antagonists (β-FNA and AM251) resulted in a significant decrease in the antinociceptive activity of AEA, confirming the involvement of opioid and cannabinoid systems in the modulation of the investigated pain reflex.
What seems surprising is that 2-AG had no significant effect on the amplitude of ETJ, as the PAG contains higher 2-AG than AEA levels under basal conditions (Maione et al., 2006; Petrosino et al., 2007) . Furthermore, 2-AG has higher a efficacy as a full CB 1 receptor agonist, despite the lower receptor affinity compared to AEA (Luk et al., 2004) . This lower efficacy of 2-AG observed in our experiments might be due to the lower levels of 2-AG accessing presynaptic CB 1 receptors and also to the fact that degradative enzyme for 2-AG is in closer proximity to the target CB 1 receptor than AEA (Figure 10) . Species-and model-specific mechanisms may further complicate the interpretation of these data (Desroches et al., 2014) .
The literature data indicate that both AEA and 2-AG can independently regulate pain sensation (Long et al., 2009a; and suggest that their individual activities are profoundly augmented upon simultaneous blockade of their respective degradative enzymes.
To verify this hypothesis in our pain model, we used the selective FAAH and MAGL inhibitors URB597 and JZL184 respectively. URB597 shows high specificity for FAAH, significantly elevating levels of AEA, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) in the CNS and in peripheral tissues.
PEA and OEA are capable of elevating levels of AEA through substrate competition at FAAH (Kathuria et al., 2003; Alhouayek and Muccioli, 2014) .
Figure 9
A scheme of the trigemino-hypoglossal reflex arc. NTS V, n.V spinal tract nucleus; N.XII, hypoglossal nerve nucleus; light-coloured triangle, the excitatory synapse; dark triangle, the inhibitory synapse.
Figure 10
Schematic representation of a promising strategy to treat orofacial pain syndromes by targeting the main EC degrading enzymes. AEA is hydrolyzed into arachidonic acid (AA) and ethanolamine primarily by FAAH in the postsynaptic neuron. 2-AG is hydrolyzed into AA and glycerol primarily by MAGL in the presynaptic neuron, although other 2-AG hydrolases (localized postynaptically) may also participate in this process. FAAH inhibitor, URB-597, reduces orofacial pain symptoms while MAGL inhibitor, JZL184, has no statistically significant effect on orofacial pain symptoms.
In our experiments, we determined that inhibition of FAAH most likely resulted in an increase in AEA levels and enhanced antinociceptive effects. On the other hand, inhibition of MAGL had no effect on the antinociceptive activity of 2-AG. Given the fact that FAAH and MAGL are localized in different regions of the neuron (e.g. FAAH postsynaptically, MAGL presynaptically) ( Figure 10 ) and regulate different ECs, the possibility exists that they may have different roles in regulating physiological functions, including nociception. It was shown that in acute pain models, effects of MAGL inhibition appear to be largely mediated by CB 1 receptors (Long et al., 2009a) , though a more prominent CB 2 -mediated component has been identified in inflammatory and neuropathic pain models (Guindon and Hohmann, 2008; Guindon et al., 2011) , perhaps unsurprisingly since 2-AG is a full agonist at CB 2 receptors while AEA is only a weak partial agonist of this receptor (Gonsiorek et al., 2000) . Full inhibition of MAGL via JZL184 produces many cannabinoid-like behaviours (Long et al., 2009a) , suggesting that this approach may share some of the unwanted side effects of cannabinoids. Furthermore, several studies have now revealed that sustained global elevation of 2-AG via genetic deletion of MAGL or persistent blockade of MAGL activity with enzyme inhibitors produces functional antagonism of the brain EC system (ECS), resulting in a profound down-regulation and desensitization of CB 1 receptors in nociception-associated regions, and a loss of analgesic phenotype (Imperatore et al., 2015; NaviaPaldanius et al., 2015) . Long et al. (2009b) developed a new antagonist, JZL195, with dual inhibitory properties, simultaneously at MAGL and FAAH. Such inhibition might offer an attractive therapeutic approach, allowing for maintaining analgesic efficacy in significantly lower doses while minimizing side effects associated with direct action of cannabinoid agonists.
Our results indicated that JZL195 enhanced the antinociceptive activity most likely through the pharmacological elevation of AEA levels in the brain and had greater antinociceptive efficacy than selective FAAH or MAGL inhibitors. Similar results were published by Long et al. (2009b) , who showed that administration of JZL195 to mice resulted in reduction of brain FAAH and MAGL activities that correlated with near-complete inhibition of both AEA and 2-AG hydrolysis. These effects were accompanied by dramatic elevations of AEA and 2-AG brain levels that approximated the increases observed with selective FAAH (URB597) or MAGL (JZL184) inhibitors.
In accordance with these data, a novel dual FAAH/MAGL inhibitor, SA-57, with markedly greater potency at FAAH than at MAGL (Niphakis et al., 2013) , was shown to produce antinociception in mouse models of neuropathic and inflammatory pain (Wilkerson et al., 2016a) . Interestingly, this compound can be used in combination with morphine to produce synergistic analgesia and even appears to alleviate tolerance to opioid analgesia. A similar effect has also been noted using low-dose MAGL inhibition via MJN110 in combination with morphine in a rodent model of neuropathic pain (Wilkerson et al., 2016b) . In our pain model, EM-2 in combination with URB597 enhanced antinociceptive activity, confirming the synergistic effects of ECs and opioids in pain suppression, being an exciting avenue for future research.
Because FAAH and MAGL inhibitors are not specific for the ECS, more work is also necessary to understand the biological roles of other lipid mediators generated by these inhibitors. Allosteric modulators of CB 1 receptors may therefore be a useful strategy for amplifying effects of ECs only at sites where they are produced and released on demand (Laprairie et al., 2017) . Nonetheless, multifunctional compounds targeting the ECS allied to inhibition of COX2 (Grim et al., 2014) , antagonism of TRPV1 (Maione et al., 2006; or in combination with opioids (Wilson-Poe et al., 2013) or non-steroidal anti-inflammatory drugs (Guindon et al., 2006) have great potential to produce a superior therapeutic profile with minimized unwanted cannabimimetic side effects. A novel therapeutic approach in many pathological states can be the possible modulation of EC activity through the regulation of their synthesis or degradation. Better characterization of endogenous cannabinoid and opioid systems and also better understanding of the function of EC signalling under physiological and pathological situations open possibilities for the design of new analgesic drugs based on the inhibition of EC catabolism (Horvath et al., 2014) . A strategy eliminating side effects accompanying CB 1 receptor activation opens safer possibilities for initial clinical studies.
In conclusion, our data show that EC and opioid pathways are involved in the descending modulatory control of trigeminal nociceptive transmission from the brainstem, a mechanism hypothesized to contribute to the pathophysiology of orofacial pain. Additionally, these effects may imply that AEA, EM-2 and inhibitors of FAAH and FAAH/MAGL could be therapeutic in orofacial pain. Clinically, the data may offer the promise of an interesting avenue for therapeutic development.
